Journal Information
Vol. 6. Issue 1.
Pages 3-4 (January - February 2010)
Vol. 6. Issue 1.
Pages 3-4 (January - February 2010)
Full text access
New drugs for rheumatoid arthritis: The industry point of view
Nuevos medicamentos contra la artritis reumatoide. El punto de vista de la industria
Visits
3608
Stephen H. Polmar
Polmar Pharma Consulting, Woodbridge, Connecticut, USA
This item has received
Article information
Full text is only aviable in PDF
References
[1.]
K.G. Saag, G.G. Teng, N.M. Patkar, J. Anuntiyo, C. Finney, J.R. Curtis, et al.
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.
Arthritis Rheum, 59 (2008), pp. 762-784
[2.]
F.C. Breedveld, M.H. Weisman, A.F. Kavanaugh, S.B. Cohen, K. Pavelka, R. Van Vollenhoven, et al.
The PREMIER study: A multicenter, randomized, double-blind, clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
Arthritis Rheum, 54 (2006), pp. 26-37
Copyright © 2010. Sociedad Española de Reumatología and Colegio Mexicano de Reumatología